Holen Sie sich die Stockscreener-App
134.66
0.27%
0.30
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$134.36
Offen:
$135.25
24-Stunden-Volumen:
3.59M
Relative Volume:
0.60
Marktkapitalisierung:
$167.19B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
18.32
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
+3.23%
1M Leistung:
+3.31%
6M Leistung:
+5.65%
1J Leistung:
+25.47%
1-Tages-Spanne:
$134.28
$136.32
1-Wochen-Bereich:
$129.42
$136.32
52-Wochen-Spanne:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
134.66 | 166.82B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,072.45 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.72 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
212.61 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.28 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.28 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Eukles Asset Management Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Allstate Corp Buys 47,838 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Acquires Tubulis for $3.15B to Expand Oncology Portfolio - Insider Monkey
GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy - TradingView
Todd Asset Management LLC Increases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Legal & General Group Plc Has $1.27 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Simplify Asset Management Inc. Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Life Cycle Investment Partners Ltd Takes $1.42 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Genus Capital Management Inc. Has $16.69 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead donates 400,000 doses of AmBisome and $9.2 mln to combat deadly visceral leishmaniasis - Новости GxP
Zacks Research Expects Lower Earnings for Gilead Sciences - MarketBeat
[Press release] FDA grants accelerated approval to Gilead’s Hepcludex® (bulevirtide-gmod), the first and only approved treatment for chronic hepatitis delta virus (HDV) - European AIDS Treatment Group
Maxim Upgrades Gilead Sciences (GILD) to ‘Buy’ - Insider Monkey
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference - MarketBeat
Axxcess Wealth Management LLC Has $4.44 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gilead Sciences leans on HIV growth as deals build oncology, inflammation pipeline - MSN
LSV Asset Management Has $508.91 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Global Retirement Partners LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains - Yahoo Finance
Gilead Sciences Inc. (NASDAQ: GILD) Holds Steady as HIV and Oncology Portfolio Drives Income - foreignpolicyjournal.com
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh Trade Ideas — BMFBOVESPA:GILD34 - TradingView
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead Sciences Inc Stock (GILD) Closed Up by 3.04% on May 22: Drivers Behind the Movement - TradingKey
Gilead wins FDA approval for first hepatitis delta treatment By Investing.com - Investing.com Nigeria
Gilead's drug wins first-ever US approval for deadly liver infection - Reuters
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment - Yahoo Finance
Gilead Sciences Gets FDA Green Light for Chronic HDV Drug - Moomoo
US FDA approves Gilead's drug for deadly liver infection - Yahoo
Gilead Sciences stock rises after FDA approves HDV treatment - Investing.com
New Gilead shot is first FDA-approved treatment for deadly hepatitis D - Stock Titan
Gilead Sciences stock rises after FDA approves HDV treatment By Investing.com - Investing.com Canada
(bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV) - Business Wire
GILD: Gilead's Trodelvy Gains Positive Opinion for TNBC Treatmen - GuruFocus
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $180 - Moomoo
Gilead Wins CHMP Positive Opinion for Breast Cancer Drug Trodelvy - Moomoo
GILD Receives Positive EMA Opinion for Trodelvy in Breast Cancer Treatment - GuruFocus
Gilead’s Trodelvy receives EU committee backing for breast cancer By Investing.com - Investing.com Australia
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer - BioSpace
Gilead’s Trodelvy receives EU committee backing for breast cancer - Investing.com
in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors - Business Wire
Keudell Morrison Wealth Management Purchases Shares of 16,022 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences acquires Tubulis for $5bn - Yahoo Finance
Gilead Sciences completes Tubulis acquisition for $5bn - Pharmaceutical Technology
Zacks Research Forecasts Weaker Earnings for Gilead Sciences - MarketBeat
PNC Financial Services Group Inc. Has $58.19 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Northwestern Mutual Wealth Management Co. Buys 13,252 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Key facts: Gilead buys Tubulis for $3.15B; remdesivir vs Bundibugyo - TradingView
Layoff Tracker: AbbVie, Novartis slash US headcount - BioSpace
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology - BioSpace
Total debt of Gilead Sciences, Inc. – BVL:GILDUS - TradingView
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Gilead Sciences Inc-Aktie (GILD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
153,779 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
May 15 '26 |
Sale |
131.29 |
28,000 |
3,676,199 |
125,779 |
1.35%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):